How Healthy Does Healthcare Look: Complementary Research on Health Insurance, Ardelyx, Electromed, CAS Medical and Capnia

May 18, 2015, 08:00 ET from Analysts Review

NEW YORK, May 18, 2015 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.  

Moments ago, Analysts Review released new research updates concerning several important developing situations including Health Insurance Innovations, Inc. (NASDAQ: HIIQ), Ardelyx, Inc. (NASDAQ: ARDX), Electromed, Inc. (NYSE MKT: ELMD), CAS Medical Systems Inc. (NASDAQ: CASM), and Capnia, Inc. (NASDAQ: CAPN). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.    

To access our full PDF reports on a complementary basis, please visit the links below.


Today's update concerns the following companies:


Full PDF Download Links (you may have to copy and paste the following links into your browser):

HIIQ Research Report: ( ),

ARDX Research Report: ( ),

ELMD Research Report: ( ),

CASM Research Report: ( ),

CAPN Research Report: ( ).



Analyst Update: Financial and Operational Results, Clinical Trials and Business Updates 

U.S. stocks mostly drifted between modest gains and losses on Friday, May 15, 2015 as investors remained cautious over weaker than expected economic data. The Dow Jones Industrial Average gained 0.11%, to finish at 18,272.56, the S&P 500 rose 0.08%, to 2,122.73, and the NASDAQ Composite ended the day at 5,048.29, down 0.05%. European stocks closed lower on Friday amid rise in the value of euro against dollar. Germany's DAX 30 lost 0.98%, France's CAC 40 fell 0.71%, and London's FTSE 100 closed 0.18% lower on Friday. Meanwhile, Asian markets painted a mixed picture on Friday. The Shanghai Composite fell as expectation of Chinese stimulus measures cooled, while Hong Kong's Hang Seng and Japan's Nikkei gained on Friday.

Health Insurance Innovations, Inc. announced its financial results for the first quarter of 2015. The Company reported revenues of $22.5 million in Q1 2015, versus $17.9 million in Q1 2014, thereby registering an increase of 25.7% YoY. The Company's total collections, also called premium equivalents, were $38.3 million, up by 23.5% over the $31 million reported in Q1 2014.

On May 12, 2015, Ardelyx, Inc. announced its financial and operational results for the first quarter of 2015. The Company reported its Licensing revenue at $3.9 million for the first quarter as against $3.2 million for Q1 2014. The Company also announced that following the completion of two Phase 2b clinical trials in constipation-predominant irritable bowel syndrome (IBS-C) and hyperphosphatemia, as well as a recent Phase 2a clinical trial in chronic kidney disease (CKD) patients, AstraZeneca is now assessing the results from all of the tenapanor trials.

On May 12, 2015, Bloomberg reported that Electromed, Inc. has announced its financial results for three and nine month periods ended March 31, 2015. The Company's net revenues for Q3 FY 2015 were $4.56 million versus $3.96 million in Q3 FY 2014. The Company reported a net income of $37,000 for Q3 FY 2015 compared to a net loss of $1,004,000 in Q3 FY 2014.

CAS Medical Systems, Inc. announced its financial results and business updates for the first quarter of 2015 on May 5, 2015. The Company reported net sales of $5.8 million for Q1 2015 versus $5.7 million reported in Q1 2014. The Company's net loss narrowed to $1.9 million or $0.08 per share in this quarter compared to a net loss of $2.2 million or $0.11 per share reported in the previous year quarter.

Capnia, Inc. announced important business updates for the first quarter of 2015 along with its financial results for the same period on May 4, 2015. In March, the Company completed a privately negotiated transaction with certain holders of its Series B warrants who agreed to exercise their Series B warrants to purchase an aggregate of 589,510 shares of Capnia's Common Stock at an exercise price of $6.50 per share, resulting in net proceeds to the Company of approximately $3.8 million.


About Analysts Review  

At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.


Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.

Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider, represented by a registered analyst has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit:

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review